Lumateperone for Autism-Related Irritability

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

Recruiting Phase 3 Interventional Study
Irritability Associated With Autism Spectrum Disorder
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 – 17
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
160 (estimated)
Sponsor
Intra-Cellular Therapies, Inc. · Industry
Who this trial is looking for

This trial is looking for children and teens aged 13 to 17 who experience irritability associated with Autism Spectrum Disorder. Participants will receive treatment and attend study visits with a responsible adult.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am aged 13 to 17 years.
  • I have a diagnosis of Autism Spectrum Disorder.
  • I experience significant irritability.
  • I have a responsible adult who can attend visits with me.
  • My adult representative has given written consent.
  • I can provide my written agreement to participate if appropriate.

You may not be able to join if

  • I have a primary psychiatric diagnosis other than Autism Spectrum Disorder.
  • I have a history or current diagnosis of Rett syndrome.
  • I have a history or current diagnosis of Fragile X syndrome.
  • I have had suicidal thoughts or attempts in the past two years.
  • I am considered a danger to myself or others.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lif…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. All patients must have a legally authorized representative LAR (eg, parent or legal guardian) who is willing and able to be responsible for the safety and well-being of the patient, provide information about the patient's condition, and accompany the patient to study visits. …
Contacts

Study Contact

844-434-4210

Participate-In-This-Study1@its.jnj.com

CONTACT